Archives

by in
Entry Author Date Location
Biogen Gets EU Panel OK for MS Drug 05/20/11 Boston
Alkermes Acquires Elan Drug Manufacturing Unit for $960M 05/09/11 Boston
Immune Design, Developer of New Vaccines, Adds Former Elan President as New CEO 04/27/11 Seattle
Biogen Shares Jump on Good News on Revenue, Oral MS Drug 04/21/11 Boston
BG Medicine Chief Speaks on Rough IPO Climate, (Finally) Going Public 04/21/11 Boston
Acorda Issued Patent on MS Drug Following Days of Speculation 04/19/11 New York
Aveo Adds Termeer to Board, Monsanto Partners With Atlas, Biogen Drug Meets Clinical Goal, & More Boston-Area Life Sciences News 04/15/11 Boston
Acorda Stock Halted as Shares Skyrocket on Patent Speculation 04/14/11 New York
Biogen Idec Passes Pivotal Trial With Oral MS Drug; Shares Climb 04/11/11 Boston
Experience Project Launches BroadCause, Putting Social Media to Work for Charitable Causes—and the Corporations Backing Them 04/05/11 San Francisco
Genzyme-Spinout Peptimmune Files for Chapter 7 Liquidation 03/23/11 Boston
RXi Sells Stock and Warrants, Cardiorobotics Raises $6.6M, ImmunoGen Dishes On New Drugs, & More Boston-Area Life Sciences News 03/04/11 Boston
FDA Wants More Data on Merck KGaA’s MS Pill As Biogen Develops Rival Therapy 03/02/11 Boston
Genzyme, After Months of Holding Out, Agrees to be Sold to Sanofi-Aventis for $20.1B 02/16/11 Boston
Biogen Board OK’s 20M Share Buyback 02/14/11 Boston
Genzyme-Sanofi Deal Might Be Close, Report Says 02/01/11 Boston
Genzyme Lets Sanofi Conduct Due Diligence 01/31/11 Boston
European Panel Rejects Biogen MS Drug 01/21/11 Boston
Dendreon’s European Plan, Williams Heads East, Allozyne Passes Clinical Trial, & More Seattle-Area Life Sciences News 01/13/11 Seattle
Allozyne Passes First Clinical Trial, Dreams Big About a Once-Monthly Multiple Sclerosis Drug 01/10/11 Seattle
Biogen Idec’s New R&D Boss, Doug Williams, Spurns Corner Office for a Return to Big Science 01/06/11 Boston
Biogen Idec Nabs Doug Williams as R&D Head, Steve Holtzman as BD Chief To Fill Out Management Team 01/05/11 Boston
Biogen Aims to Reduce PML Risk 12/22/10 Boston
Allozyne’s Next Drug, Made to Kill Two Birds With One Stone, Being Prepped for Clinic 11/16/10 Seattle
Uncle Sam Delivers $18.4M in Research Awards to Michigan Biotechs 11/05/10 Detroit
Biogen Idec Chief Aims to Make Firm More Like Biotech and Less Like Pharma with Restructuring Plan 11/04/10 Boston
Biogen Idec Offering Jobs to Quarter of San Diego Workers, While Most Get Layoff Notices 11/03/10 Boston
Biogen Idec Axes 650 Jobs, Closes San Diego Site, Bets Future on Neurology 11/03/10 Boston
PacBio IPO, Not Exactly the Netscape Moment of 2010, But a Win for Genomics 10/28/10 San Francisco
Biogen, Genentech Revamp Alliance 10/21/10 San Francisco
Page 2 of 6 « previous page · next page »

Xconomy Events Across the Network

The Napa Summit 2013: New Rules for Growth

San Francisco · 6/3/13

More Xconomy Events

Xconomy’s Most Popular

  1. Henri Termeer on Startups, Drug Prices, Getting Older (Part 1)
  2. Xconomy Opens in Texas, Expanding Roundup of Innovation Across U.S.
  3. Do You Need an Extended Warranty? Do the Math, Says SquareTrade
  4. Life After PowerPoint: Prezi Zooms Ahead in Digital Storytelling
  5. East Coast Life Sciences Roundup: Thermo, Alkermes, Acorda, Epizyme

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York, Boulder/Denver, Texas and beyond.

© 2007-2013, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Website development support from Andrew Koyfman with design support from Rob Hunter.